California Public Employees Retirement System Sells 3,400 Shares of Cempra, Inc. (CEMP)
California Public Employees Retirement System cut its stake in Cempra, Inc. (NASDAQ:CEMP) by 4.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 77,800 shares of the biotechnology company’s stock after selling 3,400 shares during the period. California Public Employees Retirement System owned approximately 0.15% of Cempra worth $292,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Asset Management One Co. Ltd. purchased a new position in shares of Cempra during the first quarter valued at $106,000. UBS Asset Management Americas Inc. purchased a new position in shares of Cempra during the first quarter valued at $140,000. Levin Capital Strategies L.P. increased its position in shares of Cempra by 56.5% in the first quarter. Levin Capital Strategies L.P. now owns 49,349 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 17,825 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cempra during the first quarter valued at $187,000. Finally, Teachers Advisors LLC increased its position in shares of Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 4,632 shares in the last quarter. 49.76% of the stock is owned by institutional investors.
Shares of Cempra, Inc. (NASDAQ:CEMP) traded down 0.926% during mid-day trading on Tuesday, reaching $2.675. 77,686 shares of the company’s stock traded hands. The company’s 50 day moving average is $3.73 and its 200 day moving average is $3.82. The company’s market cap is $140.46 million. Cempra, Inc. has a 12-month low of $2.55 and a 12-month high of $26.95.
Cempra (NASDAQ:CEMP) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.09. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The business’s revenue was down 74.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.51) EPS. On average, analysts predict that Cempra, Inc. will post ($1.01) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/california-public-employees-retirement-system-sells-3400-shares-of-cempra-inc-cemp/1529740.html.
Several research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Cempra from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Friday, August 11th. Vetr raised shares of Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 target price for the company in a report on Monday, May 1st. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 target price on shares of Cempra in a report on Thursday, August 10th. ValuEngine downgraded shares of Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Roth Capital downgraded shares of Cempra from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $11.38.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.